207 related articles for article (PubMed ID: 25399490)
1. Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer.
Liu BL; Liu SJ; Baskys A; Cheng H; Han Y; Xie C; Song H; Li J; Xin XY
BMC Cancer; 2014 Nov; 14():829. PubMed ID: 25399490
[TBL] [Abstract][Full Text] [Related]
2. Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm.
Garson K; Vanderhyden BC
Reproduction; 2015 Feb; 149(2):R59-70. PubMed ID: 25301968
[TBL] [Abstract][Full Text] [Related]
3. Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index.
Hetland TE; Kærn J; Skrede M; Sandstad B; Tropé C; Davidson B; Flørenes VA
Cancer Chemother Pharmacol; 2012 May; 69(5):1307-14. PubMed ID: 22302409
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system metastases from epithelial ovarian cancer: prognostic factors and outcomes.
Cormio G; Loizzi V; Falagario M; Calace A; Colamaria A; De Tommasi A; Selvaggi LE
Int J Gynecol Cancer; 2011 Jul; 21(5):816-21. PubMed ID: 21613959
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer.
Mariya T; Hirohashi Y; Torigoe T; Asano T; Kuroda T; Yasuda K; Mizuuchi M; Sonoda T; Saito T; Sato N
Cancer Immunol Res; 2014 Dec; 2(12):1220-9. PubMed ID: 25324403
[TBL] [Abstract][Full Text] [Related]
6. Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy.
Kastritis E; Efstathiou E; Gika D; Bozas G; Koutsoukou V; Papadimitriou C; Pissakas G; Dimopoulos MA; Bamias A
Int J Gynecol Cancer; 2006; 16(3):994-9. PubMed ID: 16803475
[TBL] [Abstract][Full Text] [Related]
7. Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer.
Wu HH; Wang PH; Yeh JY; Chen YJ; Yen MS; Huang RL; Tsai YJ; Yuan CC
Taiwan J Obstet Gynecol; 2014 Mar; 53(1):30-4. PubMed ID: 24767643
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.
Petrillo M; Fagotti A; Ferrandina G; Fanfani F; Costantini B; Vizzielli G; Pedone Anchora L; Nero C; Margariti PA; Scambia G
Gynecol Oncol; 2013 Oct; 131(1):36-41. PubMed ID: 23791829
[TBL] [Abstract][Full Text] [Related]
9. Association of Vasculogenic Mimicry Formation and CD133 Expression with Poor Prognosis in Ovarian Cancer.
Liang J; Yang B; Cao Q; Wu X
Gynecol Obstet Invest; 2016; 81(6):529-536. PubMed ID: 27160772
[TBL] [Abstract][Full Text] [Related]
10. Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy.
Yamamoto S; Tanaka K; Takeda K; Akiyama H; Ichikawa Y; Nagashima Y; Endo I
Ann Surg Oncol; 2014 Jun; 21(6):1853-61. PubMed ID: 24554065
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging.
Powless CA; Aletti GD; Bakkum-Gamez JN; Cliby WA
Gynecol Oncol; 2011 Sep; 122(3):536-40. PubMed ID: 21636114
[TBL] [Abstract][Full Text] [Related]
12. A late, solitary brain metastasis of epithelial ovarian carcinoma.
Longo R; Platini C; Eid N; Elias-Matta C; Buda T; 'Nguyen D; Quétin P
BMC Cancer; 2014 Jul; 14():543. PubMed ID: 25069863
[TBL] [Abstract][Full Text] [Related]
13. The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer.
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Pérez-Milán F; Ortiz-Quintana L
Surg Oncol; 2014 Mar; 23(1):40-4. PubMed ID: 24183480
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer.
Zhou S; Tang L; Wang H; Dai J; Zhang J; Shen L; Ng SW; Berkowitz RS
Gynecol Oncol; 2013 Oct; 131(1):69-76. PubMed ID: 23820113
[TBL] [Abstract][Full Text] [Related]
15. Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic.
Wahner Hendrickson AE; Hawthorne KM; Goode EL; Kalli KR; Goergen KM; Bakkum-Gamez JN; Cliby WA; Keeney GL; Visscher DW; Tarabishy Y; Oberg AL; Hartmann LC; Maurer MJ
Gynecol Oncol; 2015 Apr; 137(1):77-85. PubMed ID: 25620544
[TBL] [Abstract][Full Text] [Related]
16. Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma.
Kucukgoz Gulec U; Gumurdulu D; Guzel AB; Paydas S; Seydaoglu G; Acikalin A; Khatib G; Zeren H; Vardar MA; Altintas A
Arch Gynecol Obstet; 2014 Feb; 289(2):393-8. PubMed ID: 23974278
[TBL] [Abstract][Full Text] [Related]
17. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
18. Radiation therapy for epithelial ovarian cancer brain metastases: clinical outcomes and predictors of survival.
Teckie S; Makker V; Tabar V; Alektiar K; Aghajanian C; Hensley M; Beal K
Radiat Oncol; 2013 Feb; 8():36. PubMed ID: 23414446
[TBL] [Abstract][Full Text] [Related]
19. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
Chekerov R; Braicu I; Castillo-Tong DC; Richter R; Cadron I; Mahner S; Woelber L; Marth C; Van Gorp T; Speiser P; Zeillinger R; Vergote I; Sehouli J
Int J Gynecol Cancer; 2013 Feb; 23(2):268-75. PubMed ID: 23358178
[TBL] [Abstract][Full Text] [Related]
20. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
Steffensen KD; Smoter M; Waldstrøm M; Grala B; Bodnar L; Stec R; Szczylik C; Jakobsen A
Int J Oncol; 2014 May; 44(5):1736-44. PubMed ID: 24585004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
